Journal
TRANSGENIC RESEARCH
Volume 26, Issue 3, Pages 411-417Publisher
SPRINGER
DOI: 10.1007/s11248-017-0018-1
Keywords
Tamoxifen; Estrogen receptor; Recombination; Cre-activity
Categories
Funding
- Office of Research and Development, Rehabilitation Research and Development Service
- Merit Review Award from Office of Research and Development, Biomedical and Laboratory Research and Development Service, the Department of Veterans Affairs
- National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institute of Health [NIH AR54753]
- [I21 RX1440]
Ask authors/readers for more resources
Inducible Cre-ERT recombinase technology is widely used for gene targeting studies. The second generation of inducible Cre-ERT recombinase, hemizygous B6.129S-Tg(UBC-cre/ERT2)1Ejb/J (hereafter abbreviated as Cre-ERT2), a fusion of a mutated estrogen receptor and Cre recombinase, was engineered to be more efficient and specific than the original Cre-ERT. The putative mechanism of selective Cre-mediated recombination is Cre sequestration in the cytoplasm in the basal state with translocation to the nucleus only in the presence of tamoxifen. We utilized both a reporter mouse (B6.129 (Cg)-Gt(ROSA)26Sor (tm4(ACTB-tdTomato,-EGFP)Luo) /J) and endothelin converting enzyme-1 floxed transgenic mouse line to evaluate Cre-ERT2 activity. We observed spontaneous Cre activity in both settings. Unintended Cre activity is a confounding factor that has a potentially large impact on data interpretation. Thus, it is important to consider background Cre activity in experimental design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available